Category Archives: Stell Cell Research


BioCardia Announces Issuance of Two Patents Related to … – InvestorsObserver

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.

The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled Multi-Directional Steerable Catheter, with a patent term that will expire in 2035. The patent claims a fundamental design for steerable introducer sheaths, such as those used for BioCardias autologous and allogeneic cell therapy procedures, and for transseptal procedures for the treatment of cardiac arrhythmias. The design enables the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. This design is intended to enable smooth navigation and prevent whip, when a catheter in the heart suddenly jumps from one orientation to another due to the build-up of mechanical forces in the device. This patented design is incorporated in the Companys FDA-cleared Morph DNA product, a 5 French sheath equivalent, and in the Companys FDA-cleared Avance product, an 8.5 French introducer sheath indicated for transseptal procedures.

The Indian Patent Office granted the Company Patent Number 424579, entitled Steerable Endoluminal Devices and Methods for Use, with a patent term that will expire in late 2031. The patent claims a fundamental design for steerable introducer sheaths. The design is for a coil with a braid disposed coaxially about the coil, all embedded within the wall of an introducer sheath. The coil enables a robust, kink-resistant design with enhanced column support, while the braid in the catheter shaft provides for excellent torque transmission. This patent design feature has demonstrated excellent performance in the Companys Morph Access Pro product family and has been used to treat approximately 10,000 patients to-date, ranging from a two-year-old girl to a 90-year-old man.

This positive experience with the Morph DNA, Avance, and Morph AccessPro underlies our understanding of catheter navigation that informs the delivery of our higher-value biotherapeutic interventions, where we utilize steerable guide sheaths in every procedure, said BioCardia CEO Peter Altman, PhD. The acquisitions of Baylis by Boston Scientific for $1.5 billion and the acquisition of the Acutus sheath portfolio by Medtronic for $87 million last year were focused on enabling transseptal access devices, like these, that enable ablation therapies to treat cardiac arrhythmias. These acquisitions show that these steerable catheter assets are nontrivial to develop and that the intellectual property that underlies these assets has the potential to enable large market opportunities and be quite valuable.

These new patents are anticipated to strengthen the protection of BioCardias efforts with respect to its cardiovascular therapeutic approaches and provide enhanced value for all therapies developed with the Helix biotherapeutic delivery system product family.

ABOUT BIOCARDIA BioCardia, Inc. , headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement. The Company's current products include the Helix Transendocardial Biotherapeutic Delivery System, which it partners selectively with other biotherapeutic companies requiring local delivery to the heart. For more information visit: http://www.BioCardia.com .

FORWARD LOOKING STATEMENTS This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to development and value of steerable access catheter products and intellectual property and statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Anne Laluc, Marketing Email: alaluc@BioCardia.com Phone: 650-226-0120

Investor Contact: David McClung, Chief Financial Officer Email: investors@BioCardia.com Phone: 650-226-0120

Go here to see the original:
BioCardia Announces Issuance of Two Patents Related to ... - InvestorsObserver

Middle East and Africa Stem Cell Manufacturing Market Revenue to reach USD 27,428.98 million by 2029 – openPR

Middle East and Africa Stem Cell Manufacturing Market is growing with a CAGR of 10.1% in the forecast period of 2021 to 2028 and is expected to reach USD 23,505.08 million by 2028 from USD 11,076.78 million in 2020.

Middle East and Africa Stem Cell Manufacturing Market research report provides data and information about the scenario of industry which makes it easy to be ahead of the competition in today's speedily changing business environment. This market report has been structured by applying the best and standard analytical methods which are SWOT analysis and Porter's Five Forces analysis that analyse and evaluate all the primary and secondary research data and information in this report. What is more, the credible Middle East and Africa Stem Cell Manufacturing Market report intensely analyses the potential of the market with respect to existing scenario and the future prospects by considering all industry aspects of industry.

The stem cell manufacturing market is an upcoming and trending market in which stem cells are obtained from blood cells or parts of bone marrow that have the ability to regenerate themselves into specialized cells in the human body and are used for the development of various kinds of drugs, as well as to see the chemical effects of drugs on various cells and tissues, and to see whether these drugs can repair or replace damaged cells or tissues.

This stem cell manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the stem cell manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

The stem cell manufacturing market is segmented on the basis of products, application, end user and distribution channel. On the basis of products, stem cell manufacturing market is segmented into stem cell lines, instruments, consumables & kits. On the basis of application, stem cell manufacturing market is segmented into research applications, clinical applications, cell and tissue banking and others. On the basis of end user, stem cell manufacturing market is segmented into biotechnology & pharmaceutical companies, research institutes and academic institutes, cell banks and tissue banks, hospital & surgical centers and others.

Get the sample copy of report here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=middle-east-and-africa-cell-manufacturing-market

Get Full Access of Report @ https://www.databridgemarketresearch.com/reports/middle-east-and-africa-cell-manufacturing-market

Browse related reports@https://sites.google.com/view/mea-stem-cell-manufacturing/homehttps://dataanalysis580883749.wordpress.com/2023/04/04/middle-east-and-africa-stem-cell-manufacturing-market-comprehensive-analysis-and-future-estimations-by-2030/https://digitaldbmr123.blogspot.com/2023/04/middle-east-and-africa-stem-cell.htmlhttps://pastelink.net/d8oudenxhttps://writeablog.net/digitaldb/middle-east-and-africa-stem-cell-manufacturing-market-highlighting-regionalhttps://rentry.co/tstfrhttps://www.gift-me.net/blogs/33619/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Key-Highlightshttps://postheaven.net/digitaldb/middle-east-and-africa-stem-cell-manufacturing-market-comprehensive-analysishttps://www.exoltech.net/blogs/60644/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Growth-Trendshttps://homment.com/YxYWViCDaWvbtH8jOdYYhttps://www.patreon.com/posts/81016624?pr=truehttps://looku.online/blogs/8405/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Increased-demandshttps://www.expressonetwork.com/blogs/201170/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Increased-demandshttps://logcontact.com//blogs/60327/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Intelligence-Reportshttps://www.xaphyr.com/blogs/281951/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Intelligence-Reportshttps://www.soft-clouds.com/blogs/29889/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Trends-andhttps://www.4yo.us/blogs/40977/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Trends-andhttps://www.zedlike.com/blogs/71071/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Trends-andhttps://www.dr-ay.com/blogs/71241/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Analytics-Markethttps://fistpal.com/blogs/51702/Middle-East-and-Africa-Stem-Cell-Manufacturing-Market-Analytics-Markethttps://www.linkedin.com/pulse/middle-east-africa-stem-cell-manufacturing-market-revenue-dbmr/?published=thttps://twitter.com/DataBridgeDM/status/1643150912712503296?s=20https://www.exchangle.com/l/LdknUXuhttp://www.4mark.net/story/9169670/middle-east-and-africa-cell-manufacturing-market-report---industry-trends-and-forecast-to-2028-data-bridge-market-researchhttps://www.patreon.com/posts/81022228?pr=truehttps://www.scoop.it/topic/research-by-seodatabridge/p/4142396318/2023/04/04/middle-east-and-africa-cell-manufacturing-market-report-industry-trends-and-forecast-to-2028-data-bridge-market-researchhttps://padlet.com/webexecutive123/medical-devices-vcbm09u5d62nplfc/wish/2543519814https://www.tumblr.com/digitaldbmr/713666512796467200/middle-east-and-africa-cell-manufacturing-market?source=sharehttps://www.pearltrees.com/webdb/sbm-6/id64910566https://www.instapaper.com/read/1569424559https://www.databridgemarketresearch.com/reports/middle-east-and-africa-cell-manufacturing-market?utm_source=pocket_saveshttps://digitaldb.dropmark.com/1278046/32069196https://flip.it/N5OPvZhttps://www.sqworl.com/jwc7d9

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.

Read the original:
Middle East and Africa Stem Cell Manufacturing Market Revenue to reach USD 27,428.98 million by 2029 - openPR

Global Cell Culture Market Report 2023: Government Support and … – GlobeNewswire

Dublin, April 04, 2023 (GLOBE NEWSWIRE) -- The "Global Cell Culture Market by Product (Consumables (Media, Sera, Reagent), Vessel (Roller bottle, Cell Factory), Equipment (Bioreactor, Centrifuges, Incubators)), Application (mAbs, Vaccines, Diagnostics, Tissue Engineering), End User - Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

The global cell culture market is projected to reach USD 51.3 billion by 2028 from USD 27.9 billion in 2023, at a CAGR of 12.9% during the forecast period of 2023 to 2028. The growth of this market is majorly driven by the adoption of single-use technologies, growing focus on product development, growing popularity of monoclonal antibodies, and growth in cell and gene therapies and stem cell research. On the other hand, the high cost of cell biology research is restraining the growth of this market.

The supporting equipment sub-segment accounted for the largest share of the equipment segment during the forecast period

By product, the supporting equipment sub-segment accounted for the largest share of the equipment segment. Cell culture supporting equipment includes filtration systems, cell counters, carbon dioxide incubators, centrifuges, autoclaves, microscopes, biosafety cabinets, and other supporting equipment such as pipetting aids, pipettes, cell inserts, cell scrapers, cell lifters, cell spreaders, pH meters, shakers, flow cytometers, and water baths. These equipment play a vital role in maintaining optimum cell culture conditions. The increasing focus on cancer research, cell-based research and stem-cell research coupled with the rising need to meet the GMP standards and regulations is expected to fuel the segment market growth.

Europe: The second largest region in the cell culture market

Factors such as the increasing incidence of chronic diseases, rising government investments in life sciences, and increasing focus on stem cell research and regenerative medicine are driving the growth of the cell culture market in Europe. Moreover, several conferences, symposia, seminars, trade fairs, annual events, and workshops are being organized in Europe to create awareness of cell culture products.

Market Dynamics

Drivers

Restraints

Opportunities

Key Attributes:

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Cell Culture Market, by Product6.1 IntroductionTable 18 Market, by Product, 2020-2028 (USD Million)6.2 Consumables6.2.1 Sera, Media, and Reagents6.2.2 Vessels6.2.3 Accessories6.3 Equipment6.3.1 Supporting Equipment6.3.2 Bioreactors6.3.3 Storage Equipment

7 Cell Culture Market, by Application7.1 IntroductionTable 277 Market, by Application, 2020-2028 (USD Million)7.2 Biopharmaceutical Production7.2.1 Monoclonal Antibody Production7.2.2 Vaccine Production7.2.3 Other Therapeutic Protein Production7.3 Diagnostics7.4 Drug Screening & Development7.5 Tissue Engineering & Regenerative Medicine7.5.1 Cell & Gene Therapy7.5.2 Other Tissue Engineering & Regenerative Medicine Applications7.6 Other Applications

8 Cell Culture Market, by End-user8.1 IntroductionTable 330 Cell Culture Market, by End-user, 2020-2028 (USD Million)8.2 Pharmaceutical & Biotechnology Companies8.3 Hospitals & Diagnostic Laboratories8.4 Research & Academic Institutes8.5 Other End-users

9 Cell Culture Market, by Region

10 Competitive Landscape

11 Company Profiles

12 Appendix12.1 Discussion Guide12.2 Knowledgestore: The Subscription Portal12.3 Customization Options

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/vej4w1

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View original post here:
Global Cell Culture Market Report 2023: Government Support and ... - GlobeNewswire

Repairon Announces Completion of Dose-Finding Part of BioVAT … – BioSpace

GTTINGEN, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Repairon, a clinical-stage German biotech company focused on developing a novel reparative treatment for heart failure, together with the University Medical Center Gttingen (UMG) and the University Medical Center Schleswig-Holstein (UKSH), Campus Lbeck, as well as the German Center for Cardiovascular Research (DZHK) today announced the completion of enrolment and follow-up of patients in the dose-finding cohort of the BioVAT-HF-DZHK20 Phase 1/2 trial. The clinical trial is evaluating the safety and efficacy of iPSC1 -derived engineered human myocardium (EHM) as Biological Ventricular Assist Tissue (BioVAT) in Advanced Heart Failure (NCT04396899).

Dr. Rainer Knaus, Managing Director of Repairon, emphasized that "Since 2017 Repairon is the exclusive industry partner of UMG to bring the EHM therapy from the bench to the bedside. Strongly encouraged by the emerging data from the BioVAT-HF study, Repairon will continue the commercial development of the EHM technology with the aim to establish it as the therapeutic option of choice for patients with advanced heart failure."

"We are very pleased to announce the completion of the dose-finding part of our clinical study, evaluating a fundamentally new clinical strategy in the treatment of patients with advanced heart failure," said Professor Tim Seidler from the Heart Center of the University Medical Center Gttingen and Principal Investigator of the BioVAT-HF study.

"With BioVAT implantation a new therapeutic opportunity for patients with advanced heart failure and a realistic chance to avoid more invasive therapeutic procedures such as the implantation of mechanical circulatory assist devices is evolving," said Professor Ingo Kutschka Director of the Clinic for Cardiothoracic Surgery at the University Medical Center Gttingen and principle surgical investigator of the BioVAT-HF study at UMG.

"After many years of preclinical research we are pleased to see the transition of BioVAT implantation into patients with heart failure and addition of new muscle to the failing human heart," said Professor Stephan Ensminger Director of the Clinic for Cardiac and Thoracic Vascular Surgery at the University Heart Center Lbeck and principle surgical investigator of the BioVAT-HF study at UKSH, Campus Lbeck.

"We are finally seeing true remuscularization in patients with heart failure and look forward to the outcome of BioVAT-HF," said Professor Gerd Hasenfu Director of the Heart Center at the University Medical Center Gttingen.

"We are excited about our involvement in the first-in-patient, first-in-class BioVAT-HF trial, which addresses a critical unmet medical need in our patients with advanced heart failure," said Professor Ingo Eitel Director of the Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine) at the University Heart Center Lbeck.

"Advanced heart failure treatment requires new reparative therapies; with BioVAT-HF remuscularization of the failing heart is becoming a clinical possibility," said Professor Stefan Anker Charit Berlin.

The open-label, non-randomized, multi-center trial is investigating the hypothesis that cardiomyocyte implantation as BioVAT results in sustainable remuscularization and biological enhancement of myocardial performance in patients with advanced heart failure. As such it is the first of its kind in heart repair by tissue engineered remuscularization.

In the dose ranging part of the study, 10 patients with advanced heart failure with left ventricular ejection fraction 35% and NYHA III were implanted with EHM hosting an increasing number of iPSC-derived cardiomyocytes and stromal cells:

With maximal follow-up of 2 years in the low dose group and 1 year in the high dose group, the study continues to enroll patients during a transition period from Phase 1 to Phase 2 (Proof-of-Concept) based on a positive risk-benefit assessment following an adaptive clinical trial design.

"There is a huge unmet medical need for the development of new reparative treatment options for patients suffering from advanced heart failure," said Professor Wolfram-Hubertus Zimmermann, Director of the Institute of Pharmacology and Toxicology at the University Medical Center Gttingen (UMG), Co-Founder of Repairon, and BioVAT-HF Study Director. "After more than 25 years of research, the BioVAT-HF study is testing whether the addition of new heart muscle to the failing human heart can offer a new therapeutic solution for patients suffering from advanced heart failure despite optimal medical therapy. Our observation as to long-term remuscularization in BioVAT-HF is aligned with our preclinical data and our strategy to address the root-cause of heart failure."

This first-in-patient and first-in-class study is conducted by the University Medical Center Gttingen with support from Repairon, the German Center for Cardiovascular Research (DZHK), and the University Heart Center Lbeck. The interim data readout from 15 patients receiving 800 million cells is anticipated for Q2 2024, with then first data on the primary efficacy endpoints (augmentation of the target heart wall with evidence for local and global enhancement of contractility). The completion of BioVAT-HF with 35 patients treated with the safe maximal dose is expected in H2 2025.

About RepaironRepairon is a clinical-stage private German biotech company focused on developing a treatment for heart failure. The company was founded in 2014 on the pioneering work of Professor Wolfram-Hubertus Zimmermann and his team, who have developed several tissue engineering technologies with documented applicability in organ repair. Repairon's lead therapeutic candidate, engineered heart muscle (EHM), is being evaluated in a Phase 1/2 clinical trial as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF). Repairon maintains strong partnerships with the University Medical Center in Gttingen and the German Center for Cardiovascular Research (DZHK). The company is headquartered in Gttingen, Germany.

Contact

_____________________1 induced pluripotent stem cell

See original here:
Repairon Announces Completion of Dose-Finding Part of BioVAT ... - BioSpace

Direct Biologics Announces FDA Authorization to Expand Ongoing … – BioSpace

Ongoing pivotal Phase 3 EXTINGUISH ARDS trial expands to enroll hospitalized patients with moderate-to-severe ARDS, regardless of underlying etiology

ExoFlo is the first cell or cell-derived therapeutic candidate to be evaluated in a Phase 3 trial for all-cause moderate-to-severe ARDS

AUSTIN, Texas--(BUSINESS WIRE)-- Direct Biologics LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells to address multiple disease indications, announces that the U.S. Food and Drug Administration (FDA) has authorized the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo in the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS) from any underlying etiology.

ARDS is a respiratory disease characterized by a rapid onset of inflammation and fluid in the lungs with unacceptably high mortality and unsustainable treatment costs, said Mark Adams, Chief Executive Officer of Direct Biologics. We look forward to the results of our Phase 3 study given the significant survival benefit observed in our Phase 2 trial and the absence of any FDA-approved biologic for the treatment of moderate-to-severe ARDS.

The global multicenter randomized, double-blinded, placebo-controlled pivotal Phase 3 EXTINGUISH ARDS trial (NCT05354141) is designed to evaluate the safety and efficacy of ExoFlo for the treatment of all-cause moderate-to-severe ARDS. The trial is expected to enroll 320 patients ages 18-65. The trial will have two treatment arms with half of the enrolled patients receiving a placebo and half receiving up to three intravenous doses of 15 mL of ExoFlo. All patients in both arms will receive standard of care.

The primary endpoint of 60-day all-cause mortality was selected based on the significant survival benefit observed in the completed randomized Phase 2 clinical trial of ExoFlo. Secondary endpoints include ventilator-free days, oxygen-free days and ICU-free days, along with additional exploratory endpoints. In addition, the trial will evaluate the efficacy of ExoFlo in ARDS subtypes to better understand the disease process. In March 2022, ExoFlo received Regenerative Medicine Advanced Therapy, or RMAT, designation by the FDA, which provides opportunities to expedite ExoFlos clinical development for ARDS.

FDA authorization to expand our ongoing Phase 3 clinical trial to all-cause ARDS marks a defining moment for regenerative medicine. ExoFlo, designed to repair lung tissue while being a potent anti-inflammatory and immunomodulatory agent, is the first cell or cell-derived therapeutic candidate to be evaluated in a Phase 3 trial for all-cause moderate-to-severe ARDS. In fact, ExoFlo is one of a small handful of biologics that has demonstrated adequate tolerability and clinical activity to gain allowance by the FDA for Phase 3 evaluation in moderate-to-severe ARDS, said Amy Lightner, M.D., Chief Medical Officer of Direct Biologics.

About ARDS

Acute respiratory distress syndrome (ARDS) is a life-threatening condition characterized by acute and diffuse inflammatory lung injury resulting in increased fluid in the lungs, loss of ability to oxygenate and decreased lung compliance. Currently, 15% of all ICU patients and 23% of all ventilated patients in the United States are ARDS patients, which results in an annual intensive care expenditure exceeding $80 billion. The mortality rate of moderate-to-severe ARDS remains unacceptably high at 50%, despite improved ventilatory strategies such as protective ventilation and prone positioning. After decades of research, there is still no targeted or individualized therapy for the treatment of ARDS in the United States. The standard of care is still centered around optimizing mechanical ventilation and supportive care strategies without known mortality benefit.

About Direct Biologics

Direct Biologics is a late-stage biotechnology company leveraging a regenerative medicine platform which uses extracellular vesicles (EVs) secreted from mesenchymal stem cells to address multiple disease indications. Direct Biologics mission is to be the global leader in regenerative medicine through discovery, innovation, advancement of science, and treatment of patients in a safe and effective manner. Our therapeutic product candidate, ExoFlo, is designed to be a scalable, reproducible, and effective next-generation biologic that leverages our proprietary EV platform technology designed to reduce inflammation, modulate the immune system, and restore tissue through cellular regeneration. Direct Biologics is currently conducting the global Phase 3 EXTINGUISH ARDS clinical trial of ExoFlo for the treatment of hospitalized adults with moderate-to-severe acute respiratory distress syndrome (ARDS). In addition, the Company has initiated Phase 1 clinical trials with ExoFlo for the treatment of ulcerative colitis and Crohns disease, and expanded access trials in solid abdominal organ transplantation and severe ARDS patients. Direct Biologics intends to pursue additional clinical applications including perianal fistulizing Crohns disease and necrotizing enterocolitis. Headquartered in Austin, Texas, Direct Biologics also has an R&D facility at the Center for Novel Therapeutics on the campus of University of California at San Diego, and operations and order-fulfillment center in San Antonio, Texas. For more information, please visit http://www.directbiologics.com and follow us on Twitter @directbiologics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230404005769/en/

Read the original:
Direct Biologics Announces FDA Authorization to Expand Ongoing ... - BioSpace

Oncternal Therapeutics Reprioritizes Pipeline Assets and Halts … – Best Stocks

On April 3, 2023, Oncternal Therapeutics made a significant announcement regarding its pipeline assets. The company has decided to reprioritize its resources and will close both the Phase 3 study and the Phase 1/2 study of zilovertamab combined with ibrutinib. This decision was made based on the rapidly evolving therapeutic landscape, and the company has projected that its cash runway will support the clinical advancement of two other pipeline assets.

Moving forward, Oncternal will focus on the development of ONCT-808 and ONCT-534. The extended cash runway will enable initial clinical data readouts for both assets. ONCT-808 is a CAR T-cell therapy that targets ROR1 and is designed to treat patients with aggressive lymphomas. ONCT-534, on the other hand, is a novel AR inhibitor intended to help patients with resistant mCRPC.

Previously, Oncternal had agreed with the FDA on a ZILO-301 study design that aimed for regular FDA approval of zilovertamab in an end-of-phase 2 meeting in January 2022. The company also planned to conduct a study called ZILO-302, an open-label companion study of zilovertamab plus ibrutinib. However, due to the changing therapeutic landscape, the company has decided to halt the clinical development of zilovertamab in combination with ibrutinib for patients with hematologic malignancies.

In addition to its research on targeting ROR1 with zilovertamab, Oncternal has announced plans to submit an investigational new drug (IND) application for a ROR1-targeted CAR T-cell therapy, ONCT-808, in mid-2022. This decision is based on the company receiving supportive preclinical data and a pre-IND meeting with the FDA.

ONCT stock, belonging to the Health Technology sector and Pharmaceutical industry, opened at $0.79 on April 3, 2023, the same as its previous close. Throughout the day, the stocks price fluctuated between $0.77 and $0.79, with a volume of 500 shares traded, significantly lower than the average volume of 260,354 shares traded over the past three months.

The market cap of ONCT on April 3, 2023, was $46.1M, with an earnings growth rate of -32.19% in the previous year, -10.12% in the current year, and a projected earnings growth rate of 0.00% over the next five years. The revenue growth rate for ONCT in the previous year was -65.47%, and the P/E ratio was not available.

The price/sales ratio of ONCT was 35.30, and the price/book ratio was 0.74 on April 3, 2023. These ratios indicate that the stock may be overvalued compared to its peers in the industry.

In terms of ONCTs performance relative to its peers in the industry, TCON and ASMB both saw slight increases in their stock prices, while GNPX saw a decrease of -3.29%. BYSI saw the most significant increase of +4.46%.

ONCT is set to report its earnings on May 4, 2023, with an EPS forecast of -$0.22 for the current quarter. The company reported an annual revenue of $1.5M in the previous year, with an annual profit of -$44.2M. The net profit margin for ONCT was -2,964.43%, indicating that the company is not currently profitable.

The lack of available executive information for ONCT and its corporate headquarters in San Diego, California, make it difficult to assess the companys management and leadership. However, based on the available financial data, ONCTs stock performance on April 3, 2023, was not impressive, with no significant change in price and low trading volume. Investors may want to keep an eye on the stocks upcoming earnings report to gain a better understanding of its financial health and future prospects.

, 2023

On April 3, 2023, Oncternal Therapeutics Inc (ONCT) experienced a significant increase in its stock value. The companys share price rose by 733.33%, from 0.78 to 6.50, which was the median target price forecasted by six analysts for the next 12 months. The highest estimate for the stock price was 15.00, while the lowest was 3.50.

The positive outlook for ONCTs stock was driven by the companys recent developments and achievements. ONCT is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer. The companys pipeline includes several promising drug candidates that target different cancer types.

One of ONCTs most advanced drug candidates is cirmtuzumab, a monoclonal antibody that targets cancer stem cells (CSCs). CSCs are a small subpopulation of cells within tumors that are responsible for cancer progression and resistance to therapy. By targeting CSCs, cirmtuzumab has the potential to improve the efficacy of cancer treatment and prevent relapse.

ONCT recently announced positive results from a phase 1/2 clinical trial of cirmtuzumab in combination with a chemotherapy regimen for the treatment of patients with relapsed or refractory B-cell lymphoma. The trial showed that the combination therapy was well-tolerated and demonstrated promising efficacy, with an overall response rate of 75%.

ONCT also announced that it had entered into a collaboration agreement with a leading pharmaceutical company to develop a novel small molecule inhibitor of the Wnt signaling pathway. The Wnt pathway is involved in the regulation of CSCs and is a promising target for cancer therapy. The collaboration agreement provides ONCT with funding and expertise to advance the development of the drug candidate.

The positive developments and achievements of ONCT have attracted the attention of investment analysts, who have recommended buying the companys stock. The consensus rating among six polled investment analysts has been a buy rating since March, indicating a strong belief in the companys growth potential.

ONCTs financial performance in the current quarter has been mixed. The company reported a loss of $0.22 per share and sales of $260.0K. However, these financial metrics are not necessarily indicative of the companys long-term growth potential, as ONCT is still in the early stages of drug development.

Investors and analysts will be eagerly awaiting the companys next earnings report on May 04, 2023, to gain further insights into ONCTs financial performance and progress in drug development. With a promising pipeline of drug candidates and a strong consensus rating from investment analysts, ONCT is a company worth watching in the biopharmaceutical industry.

Original post:
Oncternal Therapeutics Reprioritizes Pipeline Assets and Halts ... - Best Stocks

Association between asymmetric dimethylarginine and sarcopenia … – Nature.com

Study participants

The study participants were community-dwelling older women who attended voluntary lunch events held in seven community centers in Nishinomiya City, Hyogo Japan. The inclusion criteria for this study were receipt of an annual health examination in community centers before lunch events between September 2015 and October 2015. Individuals who were<65years old, those with diabetes, cardiovascular diseases, or rheumatism, and those with an estimated glomerular filtration rate (eGFR) of<30ml/min/1.73m2 were excluded. Owing to the number of men being too small (n=16), these participants were excluded from the analysis. A further seven patients were excluded because of missing anthropometric or blood data. Of 232 older adults who participated in health examinations, 144 were included in our analysis. Of these, 85 underwent our health examination in 2017 and were included in the analysis examining the association between plasma ADMA levels and reductions in muscle mass and muscle strength over 2-years. The grip strength of one participant was not measured in the health examination conducted in 2017.

This study was conducted in accordance with the 2013 revision of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Mukogawa Womens University (approval number 15-04). All participants provided written informed consent for participation in this study and publication of the article. The sample size was determined based on the number of participants who underwent the health examination.

Blood samples were collected in the morning (from 10:00 to 11:00AM). The blood samples of 118 participants were collected following overnight fasting, whereas 26 participants self-reported eating something beforehand. Serum albumin, creatinine, and tumor necrosis factor (TNF)- levels were measured by a clinical laboratory (LSI Medience Corp., Tokyo, Japan) using the improved bromcresol method, enzymatic method, and chemiluminescent enzyme immunoassay, respectively. eGFR levels were calculated based on age and serum creatinine levels.

Anthropometric measurements were then performed and included height, weight, skeletal muscle mass, and grip strength. Weight and limb skeletal muscle mass were measured by bioimpedance analysis using the InBody 430 body composition analyzer (BioSpace Inc., Cerritos, CA, USA). Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Skeletal muscle mass index (SMI) was calculated as limb skeletal muscle mass (kg) divided by height (m) squared. The grip strength of the dominant hand was measured with the patient being in a standing position using a grip strength dynamometer (GRIP-D, Takei Scientific Instrument Co. Ltd., Japan). The higher value (kg) measure from two trials was used for the analysis. These anthropometric data were collected by well-trained staff .

Plasma samples were obtained by centrifugation of the participants blood samples using heparin and stored at30C. Plasma ADMA levels were measured in our laboratory using a competitive enzyme-linked immunosorbent assay, according to previously described methods28. Briefly, blood samples were pretreated with N-succinimidyl 3-maleimidobenzoate (SMB) and mixed with monoclonal anti-SMB-ADMA antibody. The mixtures were added to plates coated with ADMA-SMB-bovine serum albumin conjugates and incubated overnight at 4C. After labeling with horseradish peroxidase-bound secondary antibodies, ADMA levels were detected by chemiluminescence using o-phenylenediamine. The cross-reactivity of this ELISA system with L-arginine was<0.01%.

Sarcopenia is indicated by low muscle strength, low physical performance, and low height-adjusted muscle mass. We measured grip strength and skeletal muscle mass by bioimpedance analysis during the health examinations. In this study, sarcopenia was defined as a grip strength of<18kg and SMI of<5.7kg/m2 based on the definition of the Asian Working Group for Sarcopenia 2019 Consensus3.

Other demographic data including age, current medication status (antihypertension and antidislipiemia), smoking status (current smoker, previous smoker, or nonsmoker), and drinking habits (every day, sometimes, or never) were obtained.

Quantitative variables are expressed as the meanstandard deviation (SD) (median). Categorical variables are expressed as numbers (percentages). We categorized the participants into those with and thosewithout sarcopenia. The two groups were compared using unpaired t-tests for quantitative variables with normal distributions, MannWhitney U tests for quantitative variables with non-normal distributions, and chi-square tests for categorical variables. Because there is no established cutoff value for plasma ADMA levels indicative of sarcopenia, the cutoff was estimated using a receiver-operating characteristic (ROC) curve and the Youden Index. The odds ratio (OR) and 95% confidence interval (CI) for sarcopenia were determined by logistic regression analysis. The covariates of multivariate-adjusted logistic regression analysis were age (categorized by an increment of 5years), lower BMI (<18.5kg/m2), smoking (current and previous), habitual alcohol consumption (every day and sometimes), current medication for hypertension or dyslipidemia, and high serum TNF- levels (1.56pg/ml of the median value). Low serum albumin level was also a covariate; however, none of the participants had low serum albumin levels (<4.0g/dl)29. Therefore, the median was used as the reference value (<4.4g/dl). To examine the associations between plasma ADMA levels and reduced muscle mass and muscle strength, the within-subject differences in SMI and grip strength between 2015 and 2017 were compared between those with lower plasma ADMA levels and those with higher plasma ADMA levels using MannWhitney U tests. All statistical data were analyzed using SPSS v. 26.0 (IBM Corp., Armonk, NY, USA) software. Two-tailed p values of<0.05 were considered statistically significant.

Informed consent was obtained from all individual participants included in the study. Informed consent was obtained from legal guardians. Written informed consent was obtained from all participants.

Link:
Association between asymmetric dimethylarginine and sarcopenia ... - Nature.com

Hearing loss research: 5 advancements in the past year – Labiotech.eu

At present, more than 1.4 billion people live with hearing loss globally. Hearing disorders are often caused by aging, frequent exposure to loud noises and even hereditary factors. In this article, we will look at some of the latest advancements in hearing disorders research which could broaden the scope for treatments and other measures to curb auditory loss.

Hearing loss research was first documented in 1550 BC in an Ancient Egyptian medical text Ebers Papyrus, which contained a remedy for Ear that Hears Badly; an outlandish concoction of liquids like olive oil, red lead, goat urine and ant eggs, to be injected into the ear.

Then, in the 16th century, the first school to teach sign language to pupils who were deaf, was established in Spain. And, in a major breakthrough in scientific research, the first-ever pair of hearing aids, ear trumpets were developed in the 1610s, which resembled a horn.

In 1898, the first portable hearing aid which used a carbon transmitter to convert weak signals to strong ones, was developed by American electrical engineer Miller Rees Hutchinson.

However, the mass production of hearing aids only began in the early 1900s, with the devices getting more compact and convenient to use as technology progressed. Soon enough, the invention of the cochlear implant (CI) transformed therapeutic research when the first one was successfully implanted by two doctors in California, in the U.S..

Currently, there are various studies being conducted to determine how the factors contributing to hearing loss could be altered to potentially cure hearing disorders. Here are five of the latest studies on hearing disorders, which could possibly influence therapeutic research in the field.

A new research has revealed a link between hearing loss and dementia in older adults.

The research, which was published by Johns Hopkins Bloomberg School of Public Health in Maryland, U.S.A in January 2023, showed that people, specifically older adults who have been diagnosed with hearing disorders, are more likely to have dementia a condition that is associated with the decline in brain functioning where symptoms affect memory, attention and other mental abilities.

However, the greater discovery is that the likelihood of dementia was lower among those who wore hearing aids.

This study refines what weve observed about the link between hearing loss and dementia, and builds support for public health action to improve hearing care access, said Alison Huang, who is the lead author of the research paper and a senior research associate in the Bloomberg Schools Department of Epidemiology and at the Cochlear Center for Hearing and Public Health.

The medical trials studied 2,413 individuals, nearly 50% of them being over the age of 80, where the prevalence of dementia was 61% higher among those participants with moderate to severe hearing loss when compared to participants who had normal hearing. Moreover, the use of hearing aids exhibited a decrease in the prevalence of dementia by 32% in 853 participants who had moderate and severe hearing loss, indicating that treating hearing disorders could lower the risk of dementia.

The research is part of a larger investigative analysis National Health and Aging Trends Study (NHATS) which began in 2011, and is funded by the National Institute on Aging in the U.S..

Although the reason why people with hearing loss have a greater possibility of being diagnosed with dementia is yet to be determined through further clinical studies which will take place this year this breakthrough drives the need for more hearing loss therapies.

A step forward in hearing disorders research, studies have shown that there could be a potential for the reversal of hearing loss.

The research, which was conducted by Del Monte Institute for Neuroscience at the University of Rochester in New York, in the U.S., has found that although cochlear hair cells (sensory cells for hearing) cannot be repaired in human beings with hearing loss, the cells can be regenerated in birds and fish, influencing research in cell regeneration in mammals.

Previously, it was discovered that the expression of ERBB2 an active growth gene was able to activate the development of new hair cells in mammals, but the mechanism behind it was not fully understood initially, according to Patricia White, a professor of Neuroscience and Otolaryngology at the University of Rochester Medical Center. Eventually, it was found that the activation of ERBB2 triggered a cascade of cellular events where the cells began to multiply to become new sensory hair cells.

The study, published in January 2023, examined the process of regeneration of hair cells in mice using single-cell RNA sequencing, where the overactive ERBB2 was observed. It was determined that this signaling promoted stem cell-like development with the expression of proteins through the CD44 receptor which are present in the hair cells.

This discovery has made it clear that regeneration is not only restricted to the early stages of development. We believe we can use these findings to drive regeneration in adults, said Dorota Piekna-Przybylska, scientist and an author of the study.

Data from 3.5 million Danes were gathered to determine a link between traffic noise and the risk of tinnitus a condition which causes a ringing in the ears.

The study was conducted by the University of Southern Denmark (SDU) and published in Environmental Health Perspectives in February 2023, to recognize whether varying degrees of noise can result in being diagnosed with tinnitus. The research established that with an increase in every ten decibels, the risk of developing tinnitus increases by six percent, according to Manuella Lech Cantuaria, researcher and assistant professor at the Maersk Mc-Kinney-Moller Institute at SDU.

This followed a study in 2021 that found a correlation between traffic noise and dementia, particularly Alzheimers disease.

These findings contribute to the growing evidence of sounds of traffic being a detrimental pollutant affecting health, particularly of city-dwellers in congested areas.

We want to increase the focus on the health risks associated with being exposed to noise, which is not only an annoyance but also harmful to your health. Hopefully, our results can help influence urban development, said Cantuaria, who believes that noise regulation programs such as highway shielding and noise-reducing asphalt should be considered.

The efficacy of cochlear implants could be improved, according to a new study that targets the locus coeruleus a region in the brainstem that produces the hormone noradrenaline which is a neurotransmitter.

The study used rat models that were fitted with cochlear implants to determine the performance of the devices. It was observed that the stimulation of the locus coeruleus through its production of noradrenaline led to improved effectiveness of the implants.

Researchers monitored two groups of rats one set with a stimulated locus coeruleus and the other without, after training them to respond to auditory stimuli. The ones which had an activated brainstem learned faster and responded to the tasks quicker. These rats completed the auditory task within three days while those that did not receive the boost took up to 16 days, indicating the role of the locus coeruleus in reviving hearing.

Researchers of the study have pointed out the relevance of the locus coeruleus in mirroring the rat models ability and have stated the need for noninvasive mechanisms to trigger regions of the brain for further studies for hearing disorders.

Aminoglycosides, a class of antibiotics which are used as prophylactics treatments to prevent diseases and to treat infections in the urinary tract and abdomen, have been found to cause the dysfunction of autophagy the recycling of old cells in hair cells, leading to permanent hearing loss.

These findings have given rise to the research potential for therapeutic autophagy components to target aminoglycosides ototoxicity (drug-induced hearing loss), according to the research which was conducted by Indiana University School of Medicine in the U.S..

According to Bo Zhao, researcher and assistant professor at the Indiana University School of Medicine, the translocation of RIPOR2 a protein required for auditory perception caused by the binding of the aminoglycosides to the protein, affects autophagy activation, resulting in hair cell death.

The scientists found that reducing the expression of RIPOR2 prevented the death of hair cells in mice.

The proteins which were identified in the research could be significant drug targets for hearing loss which is caused by medicines like antibiotics.

New technologies related to hearing loss:

Link:
Hearing loss research: 5 advancements in the past year - Labiotech.eu

MAGENTA THERAPEUTICS, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com

The following discussion and analysis of our financial condition and results ofoperations should be read in conjunction with our consolidated financialstatements and related notes appearing at the end of this Annual Report on Form10-K. Some of the information contained in this discussion and analysis or setforth elsewhere in this Annual Report on Form 10-K, including information withrespect to our plans and strategy for our business, includes forward-lookingstatements that involve risks and uncertainties. As a result of many factors,including those factors set forth in the "Risk Factors" section of this AnnualReport on Form 10-K, our actual results could differ materially from the resultsdescribed in, or implied by, the forward-looking statements contained in thefollowing discussion and analysis.

Overview

Magenta Therapeutics, Inc. is a biotechnology company focused on improving stemcell transplantation.

In February 2023, after a review of Magenta's programs, resources andcapabilities, including anticipated costs and timelines, we announced thedecision to halt further development of our programs. Specifically, wediscontinued the MGTA-117 Phase 1/2 clinical trial in patients withrelapsed/refractory acute myeloid leukemia, or R/R AML, and myelodysplasticsyndromes, or MDS. We discontinued the MGTA-145 Phase 2 stem cell mobilizationclinical trial in patients with sickle cell disease, or SCD. Lastly, we stoppedincurring certain costs relating to MGTA-45, including manufacturing and costsrelating to certain other activities that were intended to support aninvestigative new drug application, or IND, for MGTA-45 (previously namedCD45-ADC). As a result of these decisions, we conducted a corporaterestructuring that resulted in a reduction in our workforce by 84%.

Coinciding with the decisions related to the programs and across the portfolio,we announced that we intended to conduct a comprehensive review of strategicalternatives for the company and its assets. As part of our strategic reviewprocess, we are exploring potential strategic alternatives that include, withoutlimitation, an acquisition, merger, business combination or other transaction.We are also exploring strategic transactions regarding our product candidatesand related assets, including, without limitation, licensing transactions andasset sales. There can be no assurance that the strategic review process or anytransaction relating to a specific asset, will result in Magenta pursuing such atransaction(s), or that any transaction(s), if pursued, will be completed onterms favorable to Magenta and its stockholders in the existing Magenta entityor any possible entity that results from a combination of entities. If thestrategic review process is unsuccessful, our board of directors may decide topursue a dissolution and liquidation of Magenta.

Our product candidates have been designed to improve the patient experience whenpreparing for stem cell transplant or gene therapy. Our MGTA-117 productcandidate was designed as an antibody drug conjugate, or ADC, designed todeplete CD117-expressing stem cells in the bone marrow in order to make room forsubsequently transplanted stem cells or ex vivo gene therapy products. Theprocess of making room in the bone marrow is known as conditioning, and thecurrent standard of care for conditioning utilizes chemotoxic agents. Our secondtargeted conditioning product candidate, MGTA-45, is an ADC designed toselectively target and deplete both stem cells and immune cells, and it isintended to replace the use of chemotherapy-based conditioning prior to stemcell transplant in patients with blood cancers and autoimmune diseases. Lastly,our MGTA-145 product candidate, in combination with plerixafor, is designed toimprove the stem cell mobilization process by which stem cells are mobilized outof the bone marrow and into the bloodstream to facilitate their collection forsubsequent transplant back into the body for the purpose of resetting the immunesystem.

In January 2023, we voluntarily paused dosing in our MGTA-117 Phase 1/2 clinicaltrial for MGTA-117 in patients with R/R AML and MDS after the last participantdosed in Cohort 3 in the clinical trial experienced a Grade 5 serious adverseevent, or SAE (respiratory failure and cardiac arrest resulting in death) deemedto be possibly related to MGTA-117. This safety event was reported to the FDA asthe study's third safety event which is of a type referred to as a "Suspected,Unexpected, Serious Adverse Reaction," or SUSAR. The FDA subsequently placed thestudy on partial clinical hold in February 2023.

In April 2022, we announced a plan to more narrowly focus our capital allocationon the MGTA-117 targeted conditioning program, the MGTA-45 IND-enablingactivities and the MGTA-145 stem cell mobilization efforts in sickle celldisease while also de-prioritizing other portfolio investments. We made certainreductions in our planned spending related to research platform-relatedinvestments in new disease targets, paused certain MGTA-145 investments,including the program's planned MGTA-145 dosing and administration optimizationclinical trial in healthy subjects and reduced planned general andadministrative expenses. In connection with these reductions to our plannedspending, we also reduced our workforce by 14%.

Since our inception in 2015, we have focused substantially all of our effortsand financial resources on organizing and staffing our company, businessplanning, raising capital, acquiring and developing our technology, identifyingpotential product candidates

--------------------------------------------------------------------------------

Table of Contents

and undertaking preclinical studies and clinical trials, including MGTA-117,MGTA-45 and MGTA-145. We do not have any products approved for sale and have notgenerated any revenue from product sales.

Since our inception, we have incurred significant operating losses. Net losseswere $76.5 million and $71.1 million for the years ended December 31, 2022 and2021, respectively. As of December 31, 2022, we had an accumulated deficit of$402.0 million.

We expect to continue to incur costs and expenditures in connection with theprocess of evaluating our strategic alternatives. There can be no assurance,however, that we will be able to successfully consummate any particularstrategic transaction. The process of continuing to evaluate these strategicoptions may be very costly, time-consuming and complex and we have incurred, andmay in the future incur, significant costs related to this continued evaluation,such as legal, accounting and advisory fees and expenses and other relatedcharges. A considerable portion of these costs will be incurred regardless ofwhether any such course of action is implemented or transaction is completed.Any such expenses will decrease the remaining cash available for use in ourbusiness. In addition, any strategic business combination or other transactionsthat we may consummate in the future could have a variety of negativeconsequences and we may implement a course of action or consummate a transactionthat yields unexpected results that adversely affects our business and decreasesthe remaining cash available for use in our business or the execution of ourstrategic plan. There can be no assurances that any particular course of action,business arrangement or transaction, or series of transactions, will be pursued,successfully consummated, lead to increased stockholder value, or achieve theanticipated results. Any failure of such potential transaction to achieve theanticipated results could significantly impair our ability to enter into anyfuture strategic transactions and may significantly diminish or delay any futuredistributions to our stockholders.

Should we resume development of our product candidates, our ability to generateproduct revenue sufficient to achieve profitability will depend heavily on thesuccessful development and eventual commercialization of one or more of ourproduct candidates. In addition, we will incur substantial research anddevelopments costs and other expenditures to develop such product candidatesparticularly as we:

enroll and conduct clinical trials for our product candidates;

initiate and conduct preclinical studies and clinical trials of our otherproduct candidates;

develop any other future product candidates we may choose to pursue;

seek marketing approval for any of our product candidates that successfullycomplete clinical development, if any;

maintain compliance with applicable regulatory requirements;

develop and scale up our capabilities to support our ongoing preclinicalactivities and clinical trials for our product candidates and commercializationof any of our product candidates for which we obtain marketing approval, if any;

maintain, expand, protect and enforce our intellectual property portfolio;

develop and expand our sales, marketing and distribution capabilities for ourproduct candidates for which we obtain marketing approval, if any; and

expand our operational, financial and management systems and increase personnel,including to support our clinical development and commercialization efforts andour operations as a public company.

If we resume development of our product candidates, we will not generate revenuefrom product sales unless and until we successfully complete clinicaldevelopment and obtain regulatory approval for our product candidates. If weobtain regulatory approval for any of our product candidates, we expect to incursignificant expenses related to developing our commercialization capability tosupport product sales, marketing and distribution. Further, we expect to incuradditional costs associated with operating as a public company.

Should we resume development of our product candidates, we will need substantialadditional funding to support our continuing operations. Until such time as wecan generate significant revenue from product sales, if ever, we expect tofinance our operations through a combination of equity offerings, debtfinancings, collaborations, strategic alliances and marketing and distributionor licensing arrangements. We may be unable to raise additional funds or enterinto such other agreements or arrangements when needed on favorable terms, or atall. Additionally, because of the numerous risks and uncertainties associatedwith pharmaceutical product development, we are unable to accurately predict thetiming or amount of increased expenses or when or if we will be able to achieveor maintain profitability. Even if we are able to generate product sales, we maynot become profitable. Accordingly, if we fail to raise capital or enter intonecessary strategic agreements, or fail to ever become profitable, we may haveto significantly delay, scale back or discontinue the development andcommercialization of one or more of our product candidates, and we may also beforced to reduce or terminate our operations.

--------------------------------------------------------------------------------

Table of Contents

As of December 31, 2022, we had cash, cash equivalents and marketable securitiesof $112.0 million. Based on our current operating plan, we believe that ourexisting cash, cash equivalents and marketable securities will enable us to fundour operating expenses and capital expenditure requirements for the next twelvemonths from the issuance date of this Annual Report on Form 10-K. See "Item 2.Management's Discussion and Analysis of Financial Condition and Results ofOperations - Liquidity and Capital Resources."

Impact of the COVID-19 Pandemic

The COVID-19 pandemic, including the emergence of various variants, has causedand could continue to cause significant disruptions to the U.S., regional andglobal economies and has contributed to significant volatility and negativepressure in financial markets.

We have been carefully monitoring the COVID-19 pandemic and its potential impacton our business and have taken important steps to help ensure the safety of ouremployees and their families and to reduce the spread of COVID-19 in theCambridge community. We have established a hybrid work-from-home policy for allemployees, as well as safety measures for those using our offices and laboratoryfacilities that are designed to comply with applicable federal, state and localguidelines instituted in response to the COVID-19 pandemic. We will continue toassess those measures as COVID-19-related guidelines evolve.

The future impact of the COVID-19 pandemic on our industry, the healthcaresystem and our current and future operations and financial condition will dependon future developments, which are uncertain and cannot be predicted withconfidence. These developments may include, without limitation, changes in thescope, severity and duration of the pandemic, the actions taken to contain thepandemic or mitigate its impact, including the adoption, administration andeffectiveness of available vaccines, the effect of any relaxation of currentrestrictions within the Cambridge community or regions in which our partners arelocated and the direct and indirect economic effects of the pandemic andcontainment measures. See "Item 1A. Risk Factors" for a discussion of thepotential adverse impact of COVID-19 on our business, results of operations andfinancial condition.

Components of Our Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for ourresearch activities, including our drug discovery efforts, and the developmentof our product candidates, which include:

employee-related expenses, including salaries and related costs, and stock-basedcompensation expense, for employees engaged in research and developmentfunctions;

expenses incurred in connection with the preclinical and clinical development ofour product candidates, including under agreements with contract researchorganizations, or CROs;

the cost of consultants and third-party contract development and manufacturingorganizations, or CDMOs, that manufacture drug products for use in ourpreclinical studies and clinical trials;

facilities, depreciation and other expenses, which include direct and allocatedexpenses for rent and maintenance of facilities, insurance and supplies; and

payments made under third-party licensing agreements.

We expense research and development costs to operations as incurred. Advancepayments for goods or services to be received in the future for use in researchand development activities are recorded as prepaid expenses. The prepaid amountsare expensed as the related goods are delivered or the services are performed.

Our direct research and development expenses are tracked on a program-by-programbasis and consist primarily of external costs, such as fees paid to consultants,central laboratories, contractors, CDMOs and CROs in connection with ourpreclinical and clinical development activities. We do not allocate employeecosts, costs associated with our platform technology or facility expenses,including depreciation or other indirect costs, to specific product developmentprograms because these costs are deployed across multiple product developmentprograms and, as such, are not separately classified.

Should we resume development of our product candidates, the successfuldevelopment and commercialization is highly uncertain. This is due to thenumerous risks and uncertainties, including the following:

successful completion of preclinical studies and clinical trials;

--------------------------------------------------------------------------------

Table of Contents

receipt and related terms of marketing approvals from applicable regulatoryauthorities;

raising additional funds necessary to complete clinical development of andcommercialize our product candidates;

obtaining and maintaining patent, trade secret and other intellectual propertyprotection and regulatory exclusivity for our product candidates;

making arrangements with third-party manufacturers, or establishingmanufacturing capabilities, for both clinical and commercial supplies of ourproduct candidates;

developing and implementing marketing and reimbursement strategies;

establishing sales, marketing and distribution capabilities and launchingcommercial sales of our products, if and when approved, whether alone or incollaboration with others;

acceptance of our products, if and when approved, by patients, the medicalcommunity and third-party payors;

effectively competing with other therapies;

obtaining and maintaining third-party coverage and adequate reimbursement;

protecting and enforcing our rights in our intellectual property portfolio;

maintaining a continued acceptable safety profile of the products followingapproval; and

the continuing impact of the COVID-19 pandemic on our industry, the healthcaresystem, and our current and future operations.

A change in the outcome of any of these variables with respect to thedevelopment of any of our product candidates would significantly change thecosts and timing associated with the development of that product candidate. Wemay never succeed in obtaining regulatory approval for any of our productcandidates.

Research and development activities have historically been central to ourbusiness model. Product candidates in later stages of clinical developmentgenerally have higher development costs than those in earlier stages of clinicaldevelopment, primarily due to the increased size and duration of later-stageclinical trials. We expect our research and development expenses to decrease inthe near future as we halted the development of our product candidates while weexplore strategic alternatives. Should we resume development of our productcandidates, we expect research and development costs to increase significantlyfor the foreseeable future as our product candidate development programsprogress.

Inflation generally affected us by increasing our cost of labor and clinicaltrial costs. While we do not believe that inflation had a material effect on ourfinancial condition and results of operations during the periods presented, itmay result in increased costs in the foreseeable future.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and relatedcosts, and stock-based compensation, for personnel in executive, finance andadministrative functions. General and administrative expenses also includedirect and allocated facility-related costs and insurance costs, as well asprofessional fees for legal, patent, consulting, pre-commercialization,accounting and audit services. We expect our general and administrative expensesto decrease in the near future due to recent workforce reductions. We do expectto incur significant costs, however, related to our exploration of strategicalternatives, including legal, accounting and advisory expenses and otherrelated charges.

Interest and Other Income, Net

Interest and other income, net, consists of interest income and miscellaneousincome and expense unrelated to our core operations.

Income Taxes

Since our inception, we have not recorded any U.S. federal or state income taxbenefits for the net losses we have incurred in each year or for our earnedresearch and orphan drug tax credits, due to our uncertainty of realizing abenefit from those items. As of December 31, 2022, we had net operating losscarryforwards for federal income tax purposes of $272.9 million, of which $17.5million begin to expire in 2035 and $255.4 million can be carried forwardindefinitely. As of December 31, 2022, we had net operating loss carryforwardsfor state income tax purposes of $272.6 million which begin to expire in 2035.As of December 31, 2022,

--------------------------------------------------------------------------------

Table of Contents

we also had available research and orphan drug tax credit carryforwards forfederal and state income tax purposes of $12.9 million and $3.4 million,respectively, which begin to expire in 2035 and 2030, respectively.

Critical Accounting Policies and Significant Judgments and Estimates

Excerpt from:
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

How ice hockey helped me to explain how unborn babies’ brains are … – Nature.com

Jean Mary Zarate: 00:04

Hello and welcome to Tales From the Synapse, a podcast brought to you by Nature Careers in partnership with Nature Neuroscience. Im Jean Mary Zarate, the senior editor at the journal Nature Neuroscience. And in this series, we speak to brain scientists all over the world about their life, their research, their collaborations, and the impact of their work. In episode six, we meet a researcher and author who was fascinated by the evolution of our brains and how they develop in the womb.

William Harris: 00:39

Hi, my name is William Harris, people generally call me Bill. I'm a professor emeritus at Cambridge University. Im a developmental neurobiologist, and Im the author of Zero to Birth, How the Human Brain is Built.

A developmental neurobiologist is basically someone who studies how brains develop. Its usually done in the laboratory. Its a field at the intersection of developmental biology and neuroscience.

Its carried out usually at the level of experimental animals and cells in petri dishes and things like that, rather than on human embryos.

So myself, you know I worked on fly embryos, I worked on salamander embryos, frog embryos, fish embryos. There are tons of fascinating questions about how the brain is made.

I myself got interested in it when I was a graduate student, and I was studying some mutant fruit flies. And these mutant fruit flies, they didn't see the world properly, they made visual errors. So lots of people had isolated, weird mutant flies that didn't see properly.

And when we traced the genes that were defective, mutated in those animals, we usually found that they operated at some point in the development of the visual system.

So that, you know, all these genes work to build the brain. And thats what really got me interested in it. And from that point, I just got more and more interested in how this most complicated organ develops.

And my main questions were, like, you know, wiring up, how does it get wired up? Thats what I spent most of my career doing.

I am a Canadian. I grew up in Canada, and played a lot of ice hockey. That's why there's a lot of ice hockey references in the book, analogies or metaphors in the book.

At the age when I went to university, I went to University of California at Berkeley. I was a graduate student at Caltech. My PhD supervisor was a famous guy named Seymour Benzer. And he worked on behavioural mutants of flies. I did postdoctoral work at Harvard Medical School, in the laboratories of David Hubel and Torsten Weisel, who studied the visual cortex of mammals, and how that developed.

And then I had my own career starting at the University of California, San Diego, in the biology department. And about 25 years ago, I moved to the University of Cambridge, where Ive been since.

I wrote the book because I wanted to do something useful with the perspective I had from 40 years of research and teaching of developmental neurobiology, teaching to university students.

I thought I could offer a glimpse into the field for people who wondered about such things, and have never, ever studied the subject.

I found it really difficult to make such a complicated scientific pursuit fascinating. But I tried to instill in the book some of the stories of the discoveries that have been made.

You know, how exactly were these discoveries made? And I added some colour, because I think people like to know this by trying to tie these discoveries to medical progress in neurology and psychiatry and psychology. Because so many of the things that go wrong during brain development lead to neurological or psychological syndromes.

William Harris: 05:14

Well, human brains are really different from those of every other species of animal. In fact, the brains of every species of animal are different from each other because theyve been tuned through millions of years of evolution to their particular lifestyle.

For example, an insects brain is geared to an insects world. And a human brain is geared to human affairs. But what we found out is that the instructions for making a human brain are written in the human genome, so it's largely genetic.

If you transferred a little bit of mouse embryonic brain tissue into a culture system and a human, then a brain into a culture system, theyd make, you know, a little bit of mouse brain or a little bit of human brain. Theyre genetically instructed to do that.

But what way, what way are the brains different? For example, our brains are about 10 times larger than expected for an animal of our size.

Human brains are about four times as large as chimpanzee brains, even though we weigh about the same as they do.

The architecture of human brains is different and human-specific. And the best example is the cerebral cortex, the covering of the brain where higher functions are. You know, in humans its 75% of the mass of our brain is cerebral cortex. Whereas in others, in monkeys, its only about 50%. And in most mammals, its, you know, 20% to 30%.

So its really taken over the dominant role in humans. So certain areas have enlarged, in comparison to other animals, and certain areas have not enlarged, may have shrunk.

So another key difference is the way brains develop. Just one of them, for example, is the fact that humans are born immature. Because their brains are getting bigger and bigger, they, you know, there, it seems that they constrict. Well, theres a squeezed point in evolution where, you know, in the embryo, you couldnt get an animal with a bigger brain and deliver it safely.

So, humans are born with a growing brain, and its gonna get bigger, but its as big as a mother can manage at that time. But it means that the brain is still immature when the human is born, compared to when a monkey is born. And it takes a longer time. And then it matures for a longer time postnatally too. So they spend a lot more time, humans, spend a lot more time than our closest relatives in, in learning about the world outside the womb, and that having an effect on the maturation of the brain.

We call the brain this collection of neurons thats in the head region. There are certain really circular symmetric animals like jellyfish, and they dont really have a front and a back.

And they dont have what we call a brain. They do have a nervous system, and neurons that connect to each other. But we call that a nerve net, because there isnt one centralized group where most of the neurons are.

So in evolutionary time, when bilaterally symmetric animals evolved 500-600 million years ago, and started to move in a forward direction, (you know, there was a front and a back end), it made sense to collect things at the front end that the animal was going to engage in first with the world.

So sensory apparatus, move there, smell, taste, vision, and the capacity to process the information that comes in through those senses was handled by a growing collection of neurons, which we ended up calling the brain.

If you wanted to break it down, what happens in what trimester, you could kind of think of it like this....

You start as a fertilized egg, and this egg divides and one cell becomes two, two four, four eight, eight 16 and so on. You get this ball of cells. Now, every one of those cells has the potential to make a whole human being, theyve got the genetic instructions to do everything to make a brain.

But at some point in early development, only about three weeks post-fertilization, some of the cells, some of those cells become committed to make the brain. They become the Adams and Eves, if you will, of the brain.

And they arrange themselves into groups that are the founders of different regions of the brain. There are hundreds of different regions of the brain. But these are the neural stem cells, theyre still dividing, theyre proliferating.

And theyre going to make a brain of the right size and proportions. Theyre going to make a brain with 100 billion neurons by birth.

William Harris: 11:08

Then in the second trimester, growth slows down a little bit, and some of the first neurons are generated from the neural stem cells. And connections start to be built between these first neurons. So for example, in the second trimester, you can already see some movements in the human embryo. And thats because muscle cells have connected.

Well, neurons in the spinal cord have connected with muscle cells. And neurons in the brain have connected with those motor neurons. So babies begin to kick their whole leg, move in slightly coordinated ways, bring their hands to their mouths, things like that.

You can see that connectivity is happening in the brain. I likened it to how a team is formed, and I give ice hockey analogies in the book, because thats my, that was a sport I had played and still coach.

So a coach will have tryouts and select the best players for different positions. The brain does the same thing. Maybe two neurons try out for every position, one makes it thats a little bit better at communicating, and the other one doesnt, and the one that doesnt has to commit suicide. So they go through a process called, in the business, apoptosis, where they break their own cells apart. But the survivors, once they survived, they have to last your whole life.

William Harris: 12:49

And then, in the last trimester, these neuron production grinds to a halt. The wiring up process is still going on. And this period of competition between neurons for survival, and then synaptic territory, that continues. And the neurons have to connect with each other in really precise ways and get fine tuned.

And this is still happening in the embryo, but it means that, you know, that when youre older, for example, and youre hungry, youve got neurons in your hypothalamus that will sense hunger, you know, sense the nutrition level in your brain, and neurons in your retina that can see a visual image and, you know, maybe its, this is kind of the example I give in the book, maybe its an English muffin, a picture of an English muffin that you can interpret, you learn to interpret.

And then you learn to, you know, the olfactory circuit in your nose has learned to interpret the smells received as melting butter on a freshly toasted muffin.

And then the neurons in your frontal cortex organize these pieces of information and integrate them, and send signals to the motor cortex. And the motor cortex then sends signals down the spinal cord to your motor neurons that organize a sequence of actions so that you can reach out and grab this muffin and bring it to your mouth and take a tasty bite. So a lot of that circuitry has been refined during the third trimester. Not all of it, but a lot of it.

We dont even really know how many types of neurons there are in the brain, but 1000s at least. Given that its the most complicated organ that we have, its not surprising that there are lots of different cell types. Its even been shown by recent science that every neuron in the brain has a distinct molecular identity from every other neuron in the brain. And it has a particular job.

Obvious for people are things like the rods and cones of our eyes, but the red, green, and blue-perceiving photoreceptors in the retina. So thats the three types of photoreceptors, the cone photoreceptors. And theres one type of rod cell. And then those four different photoreceptor types send their information to about 20 different next-order cell types. And they send their information to another 40 different next-order cell types, and so forth.

So by the time the image leaves the retina, the neural signal leaves the retina, its been seen by hundreds of different types of neurons, each doing a different kind of processing job.

There are lots of different types of neurons, some are numerous and tiny, and some are large, and few.

And one of the ones thats large and fewer are the dopaminergic neurons in the forebrain, whose degeneration is linked to Parkinsons disease. They're dopamine-secreting neurons. And they have exons that spread out across the cortex and many other areas of the brain. And they tone the brain, allowing people to initiate movements and things like that.

When they degenerate, then you develop Parkinsons disease. So different neurons, you can find out their function because when they when theyre gone, it reveals a defect, colour blindness, Parkinsons disease, and many other syndromes and neurological disorders are caused by defects in the formation of particular types of neurons.

William Harris: 17:03

Well, although the nervous system has started to fire up, its active before birth. And these prenatal activity patterns work, kind of like, test TV test patterns, if you remember those.

And theyre important to start to begin to tune brain function. But its only after a baby has been born that the outside world can have and does have such an influence on the activity patterns of the brain.

And so the outside world begins to fine tune the circuitry of the brain. The baby learns what its mother's face looks like, and many other things, the smell of coffee, or a muffin.

The babys brain, we say its over-wired. That means too many connections, there are too many connections. But its also under-connected because the connections arent very strong at the beginning.

And these connections need to continue to mature in the outside world. Synapses do continue to change to some extent throughout life, which is how people learn new things and forget other things.

William Harris: 18:28

Its interesting to think about the brain and the way the brain develops in two basic stages. One is building everything. And then the next stage is refining things. During the building phase youre constructing, adding more and more and more.

And during the refining phase, youre getting rid of stuff. For example, you might build a building, you might have scaffolding, and you put it up, and then you have to take it down at the end.

You may have brought in way too many bricks to build the building and have to discard some of those bricks at the end because they werent fit for purpose.

Well, the brain has a construction phase, and a destruction phase, or a decluttering phase. So first, you know, by the time a baby is born, it has more neurons than it will ever have in the rest of its life.

Neurons are dying at a faster rate than they are being born in a baby. In fact, neuronal birth has ground to a halt pretty much at the time of birth. But neurons are dying in vast numbers.

An adult human only has about half the neurons that it produced during its development. But once the brain has gone through this initial period of cell death, when its refined, got rid of the neurons that don't work so well, those neurons have to survive the rest of a lifetime because they dont divide anymore. And we dont have any neural stem cells left.

But what the survivors do is they continue to work against and with each other to gain or lose synaptic territory, and synaptic influence. And that continues on throughout life.

So, you know, a neuron might have a branch that goes to another area, and that branch might get pruned away, because someone else has taken over that territory. Those kinds of things happen, largely in childhood, but also, to a lesser extent, in an adult human.

William Harris: 20:45

My career, and particularly writing this book, has influenced the way I look at certain things, particularly my grandchildren, and one of my grandchildren features in the book a couple times.

One is about, you know, how people learn to be afraid of spiders, and whether epigenetics is involved or not.

And another is learning to speak. So babies are born with the potential to understand language. And their brains are already wired, so that they will be capable of getting it, but they cant speak yet.

So how does that happen? We talk about that in the book. But it wasnt my research so much, but it was really writing this book that changed my outlook, because I started to think about those things from a human perspective, instead of a fish brain perspective.

When I was researching, I was thinking about fish brains and fish retinas, writing a book starting to think more about human brains.

And I learned a lot about the connections between evolution and development in the brain. So how animal brains are like ours, and how theyre different from ours.

And the way its changed my outlook has, certainly, its increased my respect for what animals brains are and what animals are up, when I look at an animal.

And its also increased my respect for humans, because each one of us is born with a very unique brain. The developmental mechanisms that are used to make a brain ensures that your brain is going to be very different than my brain, its gonna be very different even if you had an identical twin brother, or sister that, you know, was grown in the same environment and had the same genes.

Theres a little bit of randomness thats thrown in. Probably our brains are the most unique things about us. We have unique faces, but our brains are even more unique. Just you cant see them.

23:06: Jean Mary Zarate

Now thats it for this episode of Tales From the Synapse. I'm Jean Mary Zarate, a senior editor at Nature Neuroscience. The producer was Don Byrne. Thanks again to Professor William Harris, and thank you for listening.

Here is the original post:
How ice hockey helped me to explain how unborn babies' brains are ... - Nature.com